IE 11 is not supported. For an optimal experience visit our site on another browser.

How is Johnson & Johnson’s vaccine different from others in phase 3 trials


Dr. Ashish Jha, dean of the Brown University School of Public Health, talks about Johnson & Johnson’s vaccine moving into phase three trials with the potential to be ready “early next year.” “The more different approaches we take, the more likely it is that we will have one, two or maybe more vaccines that end up being effective and safe,” said Dr. Jha.